Highly active anti-retroviral therapy (HAART)-induced maintenance of adaptive but not innate immune parameters is associated with protection from HIV-induced mortality
Open Access
- 23 June 2006
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 145 (2) , 271-276
- https://doi.org/10.1111/j.1365-2249.2006.03147.x
Abstract
Immunosuppression induced by the human immunodeficiency virus (HIV-1) increases the risk of death. We measured the influence of immunological and virological factors and the type of highly active anti-retroviral therapy (HAART) on this risk. Adaptive (lymphocyte) and innate (natural killer) immune correlates and maximum HIV viral loads were assessed for association with mortality using univariate and multivariate analyses. The protective effect of HAART regimens, containing protease inhibitors (PI) and/or non-nucleoside reverse transcriptase inhibitors (NNRTI) on mortality were also examined in a prospectively recorded cohort of 9621 HIV-infected individuals. From this entire cohort, 5873 HIV infected individuals (61%) have been followed-up in the HAART era and of these 499 (8·5%) have died. In multivariate analyses, CD4 counts below the 50th centile and CD8 and CD19 counts below the 25th centile were significantly associated with mortality, as was increased age (P < 0·001). Innate immune subset levels had no effect on mortality. A maximum HIV viral load greater than the 75th centile was also associated independently with mortality (P < 0·035). Exposure to either a PI or an NNRTI-containing HAART regimen, or both together, was protective against death compared with no anti-retrovirals (P < 0·001). Effective HAART-induced maintenance of the adaptive immune system (CD4, CD8 and CD19 counts) protects from HIV-related mortality.Keywords
This publication has 41 references indexed in Scilit:
- Treatment for Adult HIV InfectionJAMA, 2004
- Antiretroviral Treatment Regimens and Immune Parameters in the Prevention of Systemic AIDS-Related Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2004
- Where Does HIV Live?New England Journal of Medicine, 2004
- Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 InfectionNew England Journal of Medicine, 2004
- HIV Drug ResistanceNew England Journal of Medicine, 2004
- A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART)Journal of Antimicrobial Chemotherapy, 2004
- Nadir B cell counts are significantly correlated with the risk of Kaposi's sarcomaInternational Journal of Cancer, 2003
- A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcomaAIDS, 2003
- Prospective cohort study showing changes in the monthly incidence of Pneumocystis carinii pneumoniaPostgraduate Medical Journal, 2003
- Abnormalities of B-Cell Activation and Immunoregulation in Patients with the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1983